Peptides Market Research Report Information By Route Of Administration (Oral, Parenteral (Intravenous, Subcutanous, Intramuscular),And Others), By Age Group (Pediatric, And Adult), By Indication (Diabetes Mellitus, Obesity, Short Bowel Syndrome (SBS),Human Growth Hormone (HGH) Deficiency(Pediatrics, Adult) ,Hemophilia, Acromegaly, Hypoparathyroidism ,Cancer, Neurological disorders, Cardiovascular Disorders, Others), By Distribution Channel(Hospital Pharmacies ,Retail Pharmacies, Online Pharmacies) and by Region (North America, Europe, Asia-

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

2 MARKET INTRODUCTION

2.1 DEFINITION

2.2 SCOPE OF THE STUDY

2.3 RESEARCH OBJECTIVE

2.4 MARKET STRUCTURE

3 RESEARCH METHODOLOGY

3.1 OVERVIEW

3.2 DATA FLOW

3.2.1 DATA MINING PROCESS

3.3 PURCHASED DATABASE:

3.4 SECONDARY SOURCES:

3.4.1 SECONDARY RESEARCH DATA FLOW:

3.5 PRIMARY RESEARCH:

3.5.1 PRIMARY RESEARCH DATA FLOW:

3.6 APPROACHES FOR MARKET SIZE ESTIMATION:

3.6.1 REVENUE ANALYSIS APPROACH

3.7 DATA FORECASTING

3.7.1 DATA FORECASTING TYPE

3.8 DATA MODELING

3.8.1 MICROECONOMIC FACTOR ANALYSIS:

3.8.2 DATA MODELING:

3.9 TEAMS AND ANALYST CONTRIBUTION

4 MARKET DYNAMICS

4.1 INTRODUCTION

4.2 DRIVERS

4.2.1 GROWING AWARENESS OF PEPTIDE-BASED THERAPEUTICS

4.2.2 GROWING ACQUISITION AND AGREEMENT ASSOCIATED WITH THE PEPTIDE PRODUCTS

4.2.3 INCREASING LAUNCH OF PLATFORM TO ACCELERATE PEPTIDE DRUG DISCOVERY RESEARCH

4.3 RESTRAINTS

4.3.1 SIDE EFFECTS ASSOCIATED WITH PEPTIDE PRODUCTS

4.3.2 SHORTAGES AND SUPPLY CHAIN DISRUPTION

4.3.3 VOLUNTARY PRODUCT RECALLS BY MARKET PLAYERS

4.4 OPPORTUNITY

4.4.1 INCREASING FUNDING ASSOCIATED WITH PEPTIDE PLATFORM AND DRUG

4.4.2 INCORPORATION OF ARTIFICIAL INTELLIGENCE IN MANUFACTURING PEPTIDE-BASED THERAPEUTICS

5 MARKET FACTOR ANALYSIS

5.1 PORTER'S FIVE FORCES MODEL

5.1.1 THREAT OF NEW ENTRANTS

5.1.2 BARGAINING POWER OF SUPPLIERS

5.1.3 THREAT OF SUBSTITUTES

5.1.4 BARGAINING POWER OF BUYERS

5.1.5 INTENSITY OF RIVALRY

5.2 IMPACT OF COVID-19 ON GLOBAL PEPTIDES MARKET

5.3 REGULATORY SCENARIO, BY COUNTRY

5.4 PIPELINE ANALYSIS OVERVIEW

5.5 ALTERNATIVE TREATMENT OPTIONS

5.6 PRICING ANALYSIS, 2023

5.7 BRAND ANALYSIS

5.8 EPIDEMIOLOGY

5.9 NEW PRODUCT APPROVAL

5.10 UNMET NEED

6 GLOBAL PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION

6.1 OVERVIEW

6.2 ORAL

6.3 PARENTERAL

6.3.1 INTRAVENOUS

6.3.2 SUBCUTANOUS

6.3.3 INTRAMUSCULAR

6.4 OTHERS

7 GLOBAL PEPTIDES MARKET, BY AGE GROUP

7.1 OVERVIEW

7.2 PEDIATRIC

7.3 ADULT

8 GLOBAL PEPTIDES MARKET, BY INDICATION

8.1 OVERVIEW

8.2 COMMERCIAL AND PIPELINE MANUFACTURERS FOR PEPTIDE-BASED DRUG

8.3 DIABETES MELLITUS

8.4 OBESITY

8.5 SHORT BOWEL SYNDROME (SBS)

8.6 HUMAN GROWTH HORMONE (HGH) DEFICIENCY

8.6.1 PEDIATRICS

8.6.2 ADULT

8.7 HEMOPHILIA

8.8 ACROMEGALY

8.9 HYPOPARATHYROIDISM

8.10 CANCER

8.11 NEUROLOGICAL DISORDERS

8.12 CARDIOVASCULAR DISORDERS

8.13 OTHERS

9 GLOBAL PEPTIDES MARKET, BY DISTRIBUTION CHANNEL

9.1 OVERVIEW

9.2 HOSPITAL PHARMACIES

9.3 RETAIL PHARMACIES

9.4 ONLINE PHARMACIES

10 GLOBAL PEPTIDES MARKET, BY REGION

10.1 OVERVIEW

10.2 NORTH AMERICA

10.2.1 US

10.2.2 CANADA

10.3 EUROPE

10.3.1 GERMANY

10.3.2 FRANCE

10.3.3 UK

10.3.4 ITALY

10.3.5 SPAIN

10.3.6 REST OF EUROPE

10.4 ASIA PACIFIC

10.4.1 CHINA

10.4.2 INDIA

10.4.3 JAPAN

10.4.4 SOUTH KOREA

10.4.5 AUSTRALIA

10.4.6 REST OF ASIA PACIFIC

10.5 REST OF THE WORLD

10.5.1 MIDDLE EAST & AFRICA

10.5.2 LATIN AMERICA

11 COMPETITIVE LANDSCAPE

11.1 INTRODUCTION

11.2 MARKET SHARE ANALYSIS, 2023

11.3 COMPETITOR DASHBOARD

11.4 PUBLIC PLAYERS STOCK SUMMARY

11.5 COMPARATIVE ANALYSIS: KEY PLAYERS FINANCIAL

11.1 KEY DEVELOPMENTS & GROWTH STRATEGIES

11.1.1 PRODUCT LAUNCH

11.1.2 PRODUCT APPROVAL

11.1.3 AQUISITION

11.1.4 AGREEMENT

11.1.5 COLLABORATION

12 COMPANY PROFILES

12.1 AMGEN INC.

12.1.1 COMPANY OVERVIEW

12.1.2 FINANCIAL OVERVIEW

12.1.3 PRODUCTS OFFERED

12.1.4 KEY DEVELOPMENTS

12.1.5 SWOT ANALYSIS

12.1.6 KEY STRATEGIES

12.2 ELI LILLY AND COMPANY

12.2.1 COMPANY OVERVIEW

12.2.2 FINANCIAL OVERVIEW

12.2.3 PRODUCTS OFFERED

12.2.4 KEY DEVELOPMENTS

12.2.5 SWOT ANALYSIS

12.2.6 KEY STRATEGIES

12.3 PFIZER INC.

12.3.1 COMPANY OVERVIEW

12.3.2 FINANCIAL OVERVIEW

12.3.3 PRODUCTS OFFERED

12.3.4 KEY DEVELOPMENTS

12.3.5 SWOT ANALYSIS

12.3.6 KEY STRATEGIES

12.4 SUN PHARMACEUTICAL INDUSTRIES LTD.

12.4.1 COMPANY OVERVIEW

12.4.2 FINANCIAL OVERVIEW

12.4.3 PRODUCTS OFFERED

12.4.4 KEY DEVELOPMENTS

12.4.5 KEY STRATEGIES

12.5 MERCK KGAA

12.5.1 COMPANY OVERVIEW

12.5.2 FINANCIAL OVERVIEW

12.5.3 PRODUCTS OFFERED

12.5.4 KEY DEVELOPMENTS

12.5.5 KEY STRATEGIES

12.6 TAKEDA PHARMACEUTICAL COMPANY LIMITED

12.6.1 COMPANY OVERVIEW

12.6.2 FINANCIAL OVERVIEW

12.6.3 PRODUCT OFFERED

12.6.4 KEY DEVELOPMENTS

12.6.5 KEY STRATEGIES

12.7 ASTRAZENECA

12.7.1 COMPANY OVERVIEW

12.7.2 FINANCIAL OVERVIEW

12.7.3 PRODUCTS OFFERED

12.7.4 KEY DEVELOPMENTS

12.7.5 SWOT ANALYSIS

12.7.6 KEY STRATEGIES

12.8 NOVARTIS AG

12.8.1 COMPANY OVERVIEW

12.8.2 FINANCIAL OVERVIEW

12.8.3 PRODUCTS OFFERED

12.8.4 KEY DEVELOPMENTS

12.8.5 SWOT ANALYSIS

12.8.6 KEY STRATEGIES

12.9 SANOFI

12.9.1 COMPANY OVERVIEW

12.9.2 FINANCIAL OVERVIEW

12.9.3 PRODUCTS OFFERED

12.9.4 KEY DEVELOPMENTS

12.9.5 KEY STRATEGIES

12.10 IRONWOOD PHARMACEUTICALS, INC.

12.10.1 COMPANY OVERVIEW

12.10.2 FINANCIAL OVERVIEW

12.10.3 PRODUCTS OFFERED

12.10.4 KEY DEVELOPMENTS

12.10.5 KEY STRATEGIES

13 DATA CITATIONS

LIST OF TABLES

TABLE 1 QFD MODELING FOR MARKET SHARE ASSESSMENT

TABLE 2 REGULATORY BODIES, BY REGION

TABLE 3 PRICING ANALYSIS, 2023

TABLE 4 BRAND ANALYSIS

TABLE 5 GLOBAL PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 6 GLOBAL PEPTIDE MARKET, FOR ORAL, BY REGION, 2019–2035 (USD BILLION)

TABLE 7 GLOBAL PEPTIDE MARKET, FOR PARENTERAL, BY REGION, 2019–2035 (USD BILLION)

TABLE 8 GLOBAL PEPTIDE MARKET, FOR PARENTRAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 9 GLOBAL PEPTIDE MARKET, FOR INTRAVENOUS, BY REGION, 2019–2035 (USD BILLION)

TABLE 10 GLOBAL PEPTIDE MARKET, FOR SUBCUTANEOUS, BY REGION, 2019–2035 (USD BILLION)

TABLE 11 GLOBAL PEPTIDE MARKET, FOR INTRAMUSCULAR, BY REGION, 2019–2035 (USD BILLION)

TABLE 12 GLOBAL PEPTIDE MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)

TABLE 13 GLOBAL PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 14 GLOBAL PEPTIDE MARKET, FOR PEDIATRIC, BY REGION, 2019–2035 (USD BILLION)

TABLE 15 GLOBAL PEPTIDE MARKET, FOR ADULT, BY REGION, 2019–2035 (USD BILLION)

TABLE 16 COMMERCIAL AND PIPELINE MANUFACTURERS FOR PEPTIDE-BASED DRUG

TABLE 17 GLOBAL PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 18 GLOBAL PEPTIDE MARKET, FOR DIABETES MELLITUS, BY REGION, 2019–2035 (USD BILLION)

TABLE 19 GLOBAL PEPTIDE MARKET, FOR OBESITY, BY REGION, 2019–2035 (USD BILLION)

TABLE 20 GLOBAL PEPTIDE MARKET, FOR SHORT BOWEL SYNDROME (SBS), BY REGION, 2019–2035 (USD BILLION)

TABLE 21 GLOBAL PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY REGION, 2019–2035 (USD BILLION)

TABLE 22 GLOBAL PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 23 GLOBAL PEPTIDE MARKET, FOR PEDIATRICS, BY REGION, 2019–2035 (USD BILLION)

TABLE 24 GLOBAL PEPTIDE MARKET, FOR ADULT, BY REGION, 2019–2035 (USD BILLION)

TABLE 25 V GLOBAL PEPTIDE MARKET, FOR HEMOPHILIA, BY REGION, 2019–2035 (USD BILLION)

TABLE 26 GLOBAL PEPTIDE MARKET, FOR ACROMEGALY, BY REGION, 2019–2035 (USD BILLION)

TABLE 27 GLOBAL PEPTIDE MARKET, FOR HYPOPARATHYROIDISM, BY REGION, 2019–2035 (USD BILLION)

TABLE 28 GLOBAL PEPTIDE MARKET, FOR CANCER, BY REGION, 2019–2035 (USD BILLION)

TABLE 29 GLOBAL PEPTIDE MARKET, FOR NEUROLOGICAL DISORDERS, BY REGION, 2019–2035 (USD BILLION)

TABLE 30 GLOBAL PEPTIDE MARKET, FOR CARDIOVASCULAR DISORDERS, BY REGION, 2019–2035 (USD BILLION)

TABLE 31 GLOBAL PEPTIDE MARKET, FOR OTHERS, BY REGION, 2019–2035 (USD BILLION)

TABLE 32 GLOBAL PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 33 GLOBAL PEPTIDE MARKET, FOR HOSPITAL PHARMACIES, BY REGION, 2019–2035 (USD BILLION)

TABLE 34 GLOBAL PEPTIDE MARKET, FOR RETAIL PHARMACIES, BY REGION, 2019–2035 (USD BILLION)

TABLE 35 GLOBAL PEPTIDE MARKET, FOR ONLINE PHARMACIES, BY REGION, 2019–2035 (USD BILLION)

TABLE 36 GLOBAL PEPTIDES MARKET, BY REGION, 2019–2035 (USD BILLION)

TABLE 37 NORTH AMERICA PEPTIDES MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 38 NORTH AMERICA: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 39 NORTH AMERICA: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 40 NORTH AMERICA: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 41 NORTH AMERICA: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 42 NORTH AMERICA: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 43 NORTH AMERICA: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 44 US: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 45 US: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 46 US: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 47 US: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 48 US: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 49 US: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 50 CANADA: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 51 CANADA: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 52 CANADA: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 53 CANADA: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 54 CANADA: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 55 CANADA: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 56 EUROPE: PEPTIDES MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 57 EUROPE: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 58 EUROPE: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 59 EUROPE: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 60 EUROPE: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 61 EUROPE: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 62 EUROPE: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 63 GERMANY: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 64 GERMANY: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 65 GERMANY: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 66 GERMANY: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 67 GERMANY: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 68 GERMANY: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 69 FRANCE: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 70 FRANCE: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 71 FRANCE: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 72 FRANCE: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 73 FRANCE: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 74 FRANCE: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 75 UK: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 76 UK: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 77 UK: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 78 UK: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 79 UK: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 80 UK: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 81 ITALY: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 82 ITALY: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 83 ITALY: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 84 ITALY: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 85 ITALY: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 86 ITALY: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 87 SPAIN: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 88 SPAIN: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 89 SPAIN: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 90 SPAIN: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 91 SPAIN: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 92 SPAIN: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 93 REST OF EUROPE: PEPTIDES MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 94 REST OF EUROPE: PEPTIDES MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 95 REST OF EUROPE: PEPTIDES MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 96 REST OF EUROPE: PEPTIDES MARKET, BY INDIACTION, 2019–2035 (USD BILLION)

TABLE 97 REST OF EUROPE: PEPTIDES MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 98 REST OF EUROPE: PEPTIDES MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 99 ASIA PACIFIC PEPTIDE MARKET, BY REGION, 2019–2035 (USD BILLION)

TABLE 100 ASIA PACIFIC: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 101 ASIA PACIFIC: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 102 ASIA PACIFIC: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 103 ASIA PACIFIC: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 104 ASIA PACIFIC: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 105 ASIA PACIFIC: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 106 CHINA: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 107 CHINA: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 108 CHINA: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 109 CHINA: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 110 CHINA: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 111 CHINA: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 112 INDIA: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 113 INDIA: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 114 INDIA: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 115 INDIA: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 116 INDIA: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 117 INDIA: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 118 JAPAN: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 119 JAPAN: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 120 JAPAN: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 121 JAPAN: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 122 JAPAN: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 123 JAPAN: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 124 SOUTH KOREA: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 125 SOUTH KOREA: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 126 SOUTH KOREA: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 127 SOUTH KOREA: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 128 SOUTH KOREA: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 129 SOUTH KOREA: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 130 AUSTRALIA: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 131 AUSTRALIA: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 132 AUSTRALIA: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 133 AUSTRALIA: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 134 AUSTRALIA: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 135 AUSTRALIA: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 136 REST OF ASIA PACIFIC: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 137 REST OF ASIA PACIFIC: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 138 REST OF ASIA PACIFIC: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 139 REST OF ASIA PACIFIC: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 140 REST OF ASIA PACIFIC: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 141 REST OF ASIA PACIFIC: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 142 REST OF THE WORLD: PEPTIDE MARKET, BY COUNTRY, 2019–2035 (USD BILLION)

TABLE 143 REST OF THE WORLD: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 144 REST OF THE WORLD: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 145 REST OF THE WORLD: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 146 REST OF THE WORLD: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 147 REST OF THE WORLD: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 148 REST OF THE WORLD: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 149 MIDDLE EAST & AFRICA: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 150 MIDDLE EAST & AFRICA: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 151 MIDDLE EAST & AFRICA: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 152 MIDDLE EAST & AFRICA: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 153 MIDDLE EAST & AFRICA: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 154 MIDDLE EAST & AFRICA: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 155 LATIN AMERICA: PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2019–2035 (USD BILLION)

TABLE 156 LATIN AMERICA: PEPTIDE MARKET, FOR PARENTERAL, BY TYPE, 2019–2035 (USD BILLION)

TABLE 157 LATIN AMERICA: PEPTIDE MARKET, BY AGE GROUP, 2019–2035 (USD BILLION)

TABLE 158 LATIN AMERICA: PEPTIDE MARKET, BY INDICATION, 2019–2035 (USD BILLION)

TABLE 159 LATIN AMERICA: PEPTIDE MARKET, FOR HUMAN GROWTH HORMONE (HGH) DEFICIENCY, BY TYPE, 2019–2035 (USD BILLION)

TABLE 160 LATIN AMERICA: PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2019–2035 (USD BILLION)

TABLE 161 PRODUCT LAUNCH

TABLE 162 PRODUCT APPROVAL

TABLE 163 AQUISITION

TABLE 164 AGREEMENT

TABLE 165 COLLABORATION

TABLE 166 AMGEN INC.: PRODUCTS OFFERED

TABLE 167 ELI LILLY AND COMPANY: PRODUCTS OFFERED

TABLE 168 ELI LILLY AND COMPANY: KEY DEVELOPMENTS

TABLE 169 PFIZER INC.: PRODUCTS OFFERED

TABLE 170 PFIZER INC.: KEY DEVELOPMENTS

TABLE 171 SUN PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS OFFERED

TABLE 172 MERCK KGAA: PRODUCTS OFFERED

TABLE 173 TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCTS OFFERED

TABLE 174 TAKEDA PHARMACEUTICAL COMPANY LIMITED: KEY DEVELOPMENTS

TABLE 175 ASTRAZENECA: PRODUCT OFFERED

TABLE 176 ASTRAZENECA: KEY DEVELOPMENTS

TABLE 177 NOVARTIS AG: PRODUCTS OFFERED

TABLE 178 NOVARTIS AG: KEY DEVELOPMENTS

TABLE 179 SANOFI: PRODUCTS OFFERED

TABLE 180 SANOFI: KEY DEVELOPMENTS

TABLE 181 IRONWOOD PHARMACEUTICALS, INC.: PRODUCT OFFERED

TABLE 182 IRONWOOD PHARMACEUTICALS, INC.: KEY DEVELOPMENTS
 

LIST OF FIGURES

FIGURE 1 GLOBAL PEPTIDES MARKET: STRUCTURE

FIGURE 2 GLOBAL PEPTIDES MARKET: MARKET GROWTH FACTOR ANALYSIS (2023-2032)

FIGURE 3 DRIVER IMPACT ANALYSIS (2023-2032)

FIGURE 4 RESTRAINT IMPACT ANALYSIS (2023-2032)

FIGURE 5 PORTER'S FIVE FORCES ANALYSIS: GLOBAL PEPTIDES MARKET

FIGURE 6 GLOBAL PEPTIDES MARKET ROUTE OF ADMINISTRATION SEGMENT, 2023 & 2032 (USD BILLION)

FIGURE 7 GLOBAL PEPTIDE MARKET, BY ROUTE OF ADMINISTRATION, 2023 & 2032 (USD BILLION)

FIGURE 8 GLOBAL PEPTIDE MARKET SHARE (%), BY PRODUCT, 2023

FIGURE 9 GLOBAL PEPTIDES MARKET, AGE GROUP SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)

FIGURE 10 GLOBAL PEPTIDE MARKET, BY AGE GROUP, 2023 & 2032 (USD BILLION)

FIGURE 11 GLOBAL PEPTIDE MARKET SHARE (%), BY AGE GROUP, 2023

FIGURE 12 GLOBAL PEPTIDES MARKET, INDICATION SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)

FIGURE 13 GLOBAL PEPTIDE MARKET, BY INDICATION 2023 & 2032 (USD BILLION)

FIGURE 14 GLOBAL PEPTIDE MARKET SHARE (%), BY INDICATION, 2023

FIGURE 15 GLOBAL PEPTIDES MARKET, DISTRIBUTION CHANNEL SEGMENT ATTRACTIVENESS, 2023 & 2032 (USD BILLION)

FIGURE 16 GLOBAL PEPTIDE MARKET, BY DISTRIBUTION CHANNEL, 2023 & 2032 (USD BILLION)

FIGURE 17 GLOBAL PEPTIDE MARKET SHARE (%), BY DISTRIBUTION CHANNEL, 2023

FIGURE 18 GLOBAL PEPTIDES MARKET, BY REGION, 2023 & 2032 (USD BILLION)

FIGURE 19 GLOBAL PEPTIDES MARKET SHARE (%), BY REGION, 2023

FIGURE 20 NORTH AMERICA MARKET ANALYSIS: PEPTIDES MARKET, 2019-2032 (USD BILLION)

FIGURE 21 NORTH AMERICA: PEPTIDES MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 22 NORTH AMERICA: PEPTIDES MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 23 EUROPE MARKET ANALYSIS: PEPTIDES MARKET, 2019-2032 (USD BILLION)

FIGURE 24 EUROPE: PEPTIDES MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 25 EUROPE: PEPTIDES MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 26 ASIA PACIFIC MARKET ANALYSIS: PEPTIDE MARKET, 2019-2032 (USD BILLION)

FIGURE 27 ASIA PACIFIC: PEPTIDE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 28 ASIA PACIFIC: PEPTIDE MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 29 REST OF THE WORLD MARKET ANALYSIS: PEPTIDE MARKET, 2019-2032 (USD BILLION)

FIGURE 30 REST OF THE WORLD: PEPTIDE MARKET SHARE, BY COUNTRY, 2023 & 2032 (USD BILLION)

FIGURE 31 REST OF THE WORLD: PEPTIDE MARKET SHARE, BY COUNTRY, 2023 (%)

FIGURE 32 GLOBAL PEPTIDE MARKET PLAYERS: COMPETITIVE ANALYSIS, 2023

FIGURE 33 COMPETITOR DASHBOARD: GLOBAL PEPTIDE MARKET

FIGURE 34 AMGEN INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 35 AMGEN INC.: SWOT ANALYSIS

FIGURE 36 ELI LILLY AND COMPANY: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 37 ELI LILLY AND COMPANY: SWOT ANALYSIS

FIGURE 38 PFIZER INC.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 39 PFIZER INC.: SWOT ANALYSIS

FIGURE 40 SUN PHARMACEUTICAL INDUSTRIES LTD.: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 41 MERCK KGAA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 42 TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 43 ASTRAZENECA: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 44 ASTRAZENECA: SWOT ANALYSIS

FIGURE 45 NOVARTIS AG: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 46 NOVARTIS AG: SWOT ANALYSIS

FIGURE 47 SANOFI: FINANCIAL OVERVIEW SNAPSHOT

FIGURE 48 IRONWOOD PHARMACEUTICALS, INC.: FINANCIAL OVERVIEW SNAPSHOT